Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Hematologic Malignancy Reports
Erschienen in: Current Hematologic Malignancy Reports 5/2017

23.09.2017 | Myeloproliferative Neoplasms (B Stein, Section Editor)

Approach to MPN Symptom Assessment

verfasst von: Holly Geyer, Ruben A. Mesa

Erschienen in: Current Hematologic Malignancy Reports | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Myeloproliferative neoplasms (MPNs) are recognized for their debilitating symptom burdens. The purpose of this review is to understand the complexity of the MPN symptom burden and identify how validated MPN Patient Reported Outcome (PRO) tools may be integrated into clinical practice to assess the MPN symptom burden.

Recent Findings

Significant heterogeneity exists both within and between MPN subtypes. Surrogates of disease burden such as risk scores and MPN chronicity often fail to correlate with symptomatic burden. Validated MPN PROs allow for precise and rapid assessment of the MPN symptom burden in clinical and trial settings. Their growing use among investigators has resulted in improved understanding of how the MPN disease burden and overall patient experience is impacted by novel and traditional therapies.

Summary

PRO tools are an integral part of National Comprehensive Cancer Center (NCCN) guidelines for MPN treatment and should be regularly employed in disease burden assessment.
Literatur
1.
Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951;6(4):372–5.PubMed
2.
Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124(16):2507–13. quiz 615 CrossRefPubMedPubMedCentral
3.
Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004;117(10):755–61.CrossRefPubMed
4.
Tefferi A. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol. 2012;87(3):285–93.CrossRefPubMed
5.
•• Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27(9):1874–81. This is the most commonly used prognostic scoring system for PV. CrossRefPubMedPubMedCentral
6.
Wolanskyj AP, Lasho TL, Schwager SM, McClure RF, Wadleigh M, Lee SJ, et al. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol. 2005;131(2):208–13.CrossRefPubMed
7.
Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, et al. Development and validation of an international prognostic score of thrombosis in World Health Organization—essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120(26):5128–33. quiz 252
8.
Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391–405.CrossRefPubMedPubMedCentral
9.
Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379–90.CrossRefPubMed
10.
Tefferi A, Lasho TL, Finke CM, Knudson RA, Ketterling R, Hanson CH, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia. 2014;28(7):1472–7.CrossRefPubMed
11.
Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, et al. DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392–7.CrossRefPubMed
12.
Scherber R, Dueck AC, Johansson P, Barbui T, Barosi G, Vannucchi AM, et al. The myeloproliferative neoplasm symptom assessment form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood. 2011;118(2):401–8.CrossRefPubMed
13.
14.
Geyer HL, Scherber RM, Dueck AC, Kiladjian JJ, Xiao Z, Slot S, et al. Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. Blood. 2014;123(24):3803–10.CrossRefPubMedPubMedCentral
15.
• Geyer HL, Andreasson B, Kosiorek HE, Dueck AC, Scherber RM, Martin KA, et al. The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: an analysis by the MPN QOL international study group. Cancer. 2016;122(12):1888–96. This study was among the first demonstrating the multifactorial nature of MPN symptom development.
16.
• Geyer HL, Dueck AC, Emanuel RM, Cannon K, Kiladjian J-J, Slot S, et al. Insomnia, quality of life and MPN symptom burden: an analysis by the MPN quality of life international study group (MPN-QOL ISG). Blood. 2013;122(21):4087. This was the first article to demonstrate differences in symptomatic burden by patient gender.
17.
Geyer HL, Kosiorek H, Dueck AC, Scherber R, Slot S, Zweegman S, et al. Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL international working group. Haematologica. 2017;102(1):85–93.CrossRefPubMedPubMedCentral
18.
Geyer HL, Scherber RM, Dueck AC, Kiladjian JJ, Xiao Z, Slot S, et al. Symptom severity and clinical variables of polycythemia vera patients with splenomegaly, phlebotomy requirements and/or hydroxyurea use: a retrospective evaluation of 1334 patients. Blood ASH Annual Meeting 2014;124(21).
19.
Emanuel R, Marchioli R, Dueck A, Geyer HL, Finazzi G, Cavazzina R, Masciulli, A, et al. Impact of hematocrit on symptom burden among polycythemia vera patients. European Hematology Association Annual Meeting Abstracts 2013;276.
20.
Geyer H, Scherber RM, Kosiorek H, Dueck AC, Kiladjian J-J, Xiao Z, et al. Symptom burden profile in myelofibrosis patients with thrombocytopenia: lessons and unmet needs. Blood. 2015;126:4080.
21.
• Dueck AC, Cleeland CS, Dantzer R, Sloan J, Verstovsek S, Emanuel RM, et al. Cytokine profile changes in 309 myelofibrosis patients: comparison of JAK1/JAK2 inhibitor therapy vs. placebo—correlative analysis from the Comfort-I trial. Blood. 2013;122(21):4074. This was the first publication documenting changes in the MPN symptom burden over time by individual symptoms.
22.
• Scherber RM, Geyer H, Harrison CN, Kosiorek HE, Dueck AC, Kiladjian J-J, et al. Impact of disease duration upon symptom burden amongst patients with myeloproliferative neoplasms (MPNs). Blood. 2015;126:4073. In this investigation, it was demonstrated that length of disease is not necessarily a determinant of MPN disease severity.
23.
Mesa RA, Niblack J, Wadleigh M, Verstovsek S, Camoriano J, Barnes S, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer. 2007;109(1):68–76.CrossRefPubMed
24.
Mesa RA, Schwager S, Radia D, Cheville A, Hussein K, Niblack J, et al. The myelofibrosis symptom assessment form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res. 2009;33(9):1199–203.CrossRefPubMedPubMedCentral
25.
Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012;30(33):4098–103.CrossRefPubMedPubMedCentral
26.
Eremenco S, Oko-Osi H, Arnold B, Savic L, Sterling K, Athearn R, et al. Translation and linguistic validation of the modified myeloproliferative neoplasm symptom assessment form—total symptom score (MMPN-SAF TSS) for use in 26 countries. Value Health. 2015;18(7):A471–2.CrossRefPubMed
27.
Pardanani A, Harrison C, Cortes JE, Cervantes F, Mesa RA, Milligan D, et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial. JAMA Oncol. 2015;1(5):643–51.CrossRefPubMed
28.
•• Mesa R, Vannucchi AM, Yacoub A, Zachee P, Garg M, Lyons R, et al. The efficacy and safety of continued hydroxyurea therapy versus switching to ruxolitinib in patients with polycythemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF). Blood. 2014;124(21):3168. This was among the first publcations demonstraing the impact of JAK2 inhibition on PV symptoms.
29.
Mesa RA, Kantarjian H, Tefferi A, Dueck A, Levy R, Vaddi K, et al. Evaluating the serial use of the myelofibrosis symptom assessment form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer. 2011;117(21):4869–77.CrossRefPubMedPubMedCentral
30.
Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799–807.CrossRefPubMedPubMedCentral
31.
Emanuel R, Dueck AC, Geyer HL, Kiladjian J-J, Slot S, Zweegman S, et al. Myeloproliferative (MPN) symptom burden response thresholds: assessment of MPN-SAF TSS quartiles as potential markers of symptom response. Blood. 2013;122:4067.
32.
Scherber R, Dueck A, Geyer HL, Kosiorek H, Kiladijan JJ, Slot S, et al. Symptoms, risk classification and spleen size in JAK2 inhibitor-naive myelofibrosis: Implications for JAK2 inhibitor treatment. European Hematology Association Annual Meeting Abstracts: E1345.
33.
•• Scherber RM, Kosiorek HE, Senyak Z, Dueck AC, Clark MM, Boxer MA, et al. Comprehensively understanding fatigue in patients with myeloproliferative neoplasms. Cancer. 2016;122(3):477–85. This investigation comprehensively reviewed the the prevalent and burdensome MPN symptom of fatigue. CrossRefPubMed
34.
Mesa R, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S, et al. Impact of myeloproliferative neoplasms (MPNs) on patients’ overall health and productivity: results from the MPN LANDMARK SURVEY in the United States. Blood. 2014;124(21):3183.
35.
Scherber RM, Knapper S, Fox S, Kosiorek HE, Shah M, Abdi-Moradi S, et al. Assessment and validation of the EQ-5D among a population of myeloproliferative neoplasm patients. Blood. 2015;126:5179.
36.
• Gowin K, Eckert R, Huberty J, Gowin KL, Ginos B, Kosiorek HE, et al. Impact of weight on symptom burden outcomes in myeloproliferative neoplasm patients participating in an online yoga intervention. Blood. 2016;128:5481. This was the first dedicated non-pharmacological intervention for MF symptom management.
37.
Scherber RM, Senyak Z, Kosiorek HE, Dueck AC, Clark MM, Boxer M, et al. Treating depression in the myeloproliferative neoplasms: the role and implications of poorly controlled symptoms and psychosocial factors. Blood. 2016;128:5474.
38.
Mesa RA, Li CY, Schroeder G, Tefferi A. Clinical correlates of splenic histopathology and splenic karyotype in myelofibrosis with myeloid metaplasia. Blood. 2001;97(11):3665–7.CrossRefPubMed
39.
Geyer HL, Scherber R, Dueck A, Kiladjian J, Xiao Z, Slot S, et al. Impact of splenomegaly on myelofibrosis symptoms and association with clinical features: an analysis by the MPN Quality of Life International Study Group. European Hematology Association Annual Meeting Abstracts (E1339). 2016.
Metadaten
Titel
Approach to MPN Symptom Assessment
verfasst von
Holly Geyer
Ruben A. Mesa
Publikationsdatum
23.09.2017
Verlag
Springer US
Erschienen in
Current Hematologic Malignancy Reports / Ausgabe 5/2017
Print ISSN: 1558-8211
Elektronische ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-017-0399-5

Weitere Artikel der Ausgabe 5/2017

Current Hematologic Malignancy Reports 5/2017 Zur Ausgabe

Myeloproliferative Neoplasms (B Stein, Section Editor)

Familial MPN Predisposition

Myelodysplastic Syndromes (M Savona, Section Editor)

Patient-Reported Outcomes in Myelodysplastic Syndromes and MDS/MPN Overlap Syndromes: Stepping Onto the Stage with Changing Times

Myelodysplastic Syndromes (M Savona, Section Editor)

Molecular Data and the IPSS-R: How Mutational Burden Can Affect Prognostication in MDS

Myelodysplastic Syndromes (M Savona, Section Editor)

Therapy for Chronic Myelomonocytic Leukemia in a New Era

CART and Immunotherapy (M Ruella, Section Editor)

Immune Dysfunction in Non-Hodgkin Lymphoma: Avenues for New Immunotherapy-Based Strategies

Myelodysplastic Syndromes (M Savona, Section Editor)

Nuances of Morphology in Myelodysplastic Diseases in the Age of Molecular Diagnostics

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise